Dose-dense adjuvant chemotherapy for primary breast cancer.
Adjuvant chemotherapy has been proven to reduce significantly the risk for relapse and death in women with operable breast cancer. Nevertheless, the prognosis for patients presenting with extensive axillary lymph node involvement remains suboptimal. In an attempt to improve on the efficacy of existing chemotherapy, a phase III intergroup trial led by the Cancer and Leukemia Group B (CALGB 97-41) was designed, which tested a mathematical model of tumor growth based on the Norton-Simon hypothesis. This hypothesis, developed about 3 decades ago, and the kinetic model derived from it, created the basis of the concepts of dose density and sequential therapy, both of which were tested in CALGB 97-41. This large prospective randomized trial demonstrated that shortening the time interval between each chemotherapy cycle while maintaining the same dose size resulted in significant improvements in disease-free and overall survival in patients with node-positive breast carcinoma. This finding is highly relevant and has immediate implications for clinical practice.
Fornier
Monica
M
Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. fornierm@mskcc.org
Norton
Larry
L
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic
J Clin Oncol. 1997 May;15(5):1858-69
9164196
JAMA. 1995 Feb 15;273(7):542-7
7837388
CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29
14974761
J Clin Oncol. 2003 Apr 15;21(8):1431-9
12668651
N Engl J Med. 2003 Jul 3;349(1):7-16
12840087
Cancer Treat Rep. 1986 Jan;70(1):3-7
3943114
Ann Oncol. 2004 Sep;15(9):1425-31
15319250
J Clin Oncol. 1999 Apr;17(4):1118
10561169
J Clin Oncol. 2005 Jun 1;23(16):3686-96
15897552
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727-33
526911
J Clin Oncol. 2001 Feb 1;19(3):602-11
11157009
Lancet. 1998 Sep 19;352(9132):930-42
9752815
J Clin Oncol. 2003 Mar 15;21(6):976-83
12637460
Cancer Res. 1988 Dec 15;48(24 Pt 1):7067-71
3191483
Clin Cancer Res. 2004 Sep 1;10(17):5754-61
15355903
J Clin Oncol. 1999 Nov;17(11):3374-88
10550131
J Clin Oncol. 1999 Jan;17(1):93-100
10458222
Clin Cancer Res. 2001 Dec;7(12):3934-41
11751485
J Clin Oncol. 1986 Aug;4(8):1162-70
3525765
J Clin Oncol. 2003 Mar 1;21(5):843-50
12610183